Rankings / Longevity — Peptides
Humanin
Longevity · Mitochondrial-derived peptide
Tier C+
Bottom line
Read Off Label grades Humanin as C+ (5.3/10) based on preclinical evidence, unknown / varies benefit magnitude, and a low-risk safety profile.
Declines ~60-70% from age 20 to 80 in humans.
Typical use: No standard clinical dose; usually studied 0. — Research chemical.
What this is
Declines ~60-70% from age 20 to 80 in humans. Elevated in centenarians and their offspring. Preclinical: neuroprotective in Alzheimer's models. No human RCTs with hard endpoints — mostly observational biomarker work.
Mechanism
24-amino acid peptide from 16S rRNA; cytoprotective — blocks Bax-induced apoptosis; associated with insulin sensitivity and IGF-1 signaling; declines with age
Dose & route
No standard clinical dose; usually studied 0.5-2 mg/day in research
Citations
- https://pubmed.ncbi.nlm.nih.gov/32404601/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC7525063/
- https://www.aging-us.com/article/102329/text
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Humanin work?
- Read Off Label rates the evidence for Humanin as Preclinical and the benefit magnitude as unknown / varies, producing an overall grade of C+ (5.3/10). Declines ~60-70% from age 20 to 80 in humans.
- Is Humanin safe?
- Humanin has a low risk profile in published human data. Legal status: Research chemical. This is not medical advice — see the disclaimer.
- What is the typical dose for Humanin?
- No standard clinical dose; usually studied 0.5-2 mg/day in research
- How does Humanin work?
- 24-amino acid peptide from 16S rRNA; cytoprotective — blocks Bax-induced apoptosis; associated with insulin sensitivity and IGF-1 signaling; declines with age
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.